Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, released preclinical data today highlighting the pharmacological properties of ex vivo programmed hematopoietic cells sourced from mobilized peripheral blood at the 56th Annual Meeting and Exposition of the American Society of Hematology . Using a newly-identified combination of two small molecule modulators, scientists from Fate Therapeutics demonstrated that both T-cells and CD34+ cells from mobilized peripheral blood can be modulated ex vivo , with preclinical evidence pointing to the programmed hematopoietic cells having improved therapeutic potential.
http://ift.tt/1tYdqZI
http://ift.tt/1tYdqZI
No comments:
Post a Comment